Abstract
Nearly all patients with metastatic prostate cancer (PC) become resistant to the initial approach with androgen deprivation therapy (ADT), developing the state known as metastatic castration-resistant prostate cancer (mCRPC). For nearly a decade, chemotherapy with docetaxel has been the only established standard of care in this setting. In recent years, treatment of mCRPC has changed dramatically due to the improvement in the understanding of CRPC biology, which has revealed that during the progression to the castrate status, PC cells remain dependent on androgens and on the androgen receptor (AR) signaling pathway. Multiple novel agents that have demonstrated to improve OS, symptom control, and QoL in mCRPC have been approved, including sipuleucel-T, cabazitaxel, abiraterone acetate, enzalutamide, and radium-223. The optimal sequencing and combination of these treatments still need to be defined. However, chemotherapy with docetaxel and cabazitaxel remains an important therapeutic option for patients with mCRPC, with potential clinical effect on bone metastases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Attard G, Parker C, Eeles RA et al (2016) Prostate cancer. Lancet 387:70–82
Ryan CJ, Small EJ (2003) Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 62(Suppl 1):87–94
Tannock IF (1985) Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013–1021
Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756–1764
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
Mostaghel EA, Page ST, Lin DW et al (2007) Intra-prostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033–5041
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005
Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197
Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223
Gillessen S, Omlin A, Attard G et al (2016) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26(8):1589–1604
Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357
Beltran H, Yelensky R, Frampton GM et al (2013) Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63:920–926
Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:1697–1708
Hager S, Ackermann CJ, Joerger M et al (2016) Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review. Ann Oncol 27:975–984
Petrylak DP (2014) Practical guide to the use of chemotherapy in castration resistant prostate cancer. Can J Urol 21(Suppl 1):77–83
Hurwitz M (2015) Chemotherapy in prostate cancer. Curr Oncol Rep 17:44–53
Vignani F, Bertaglia V, Buttigliero C et al (2016) Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev 44:61–73
Eisenberger MA, Simon R, O'Dwyer PJ et al (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827–841
Schweizer T, Antonarakis ES (2014) Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl 16:334–340
Glode LM, Barqawi A, Crighton F et al (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643–1648
Perry CM, McTavish D (1995) Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7:49–74
Bracarda S, Tonato M, Rosi P et al (2000) Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study. Cancer 88:1438–1444
Moore MJ, Osoba D, Murphy K et al (1994) Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689–694
Kantoff PW, Block C, Letvak L et al (1993) 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. Am J Clin Oncol 16:489–491
Osoba D, Tannock IF, Ernst DS, Neville AJ (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17:1654–1663
Kantoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results oft he Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506–2513
Michaelson MD, Oudard S, Ou Y-C et al (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration resistant prostate cancer. J Clin Oncol 32:76–82
Green AK, Corty RW, Wood WA et al (2015) Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure. Oncologist 20:516–522
Desai A, Mitchison TJ (1997) Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 13:83–117
Cheetham P, Petrylak DP (2013) Tubulin-targeted agents including docetaxel and cabazitaxel. Cancer J 19:59–65
Gan L, Chen S, Wang Y et al (2009) Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 69:8386–8394
Zhu ML, Horbinski CM, Garzotto M et al (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992–8002
Darshan MS, Loftus MS, Thadani-Mulero M et al (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71:6019–6029
Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26:14–18
Friedland D, Cohen J, Miller R Jr et al (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26:19–23
Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8–15
Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245
Machiels JP, Mazzeo F, Clausse M et al (2008) Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 26:5261–5268
Kelly WK, Halabi S, Carducci M et al (2012) randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534–1540
Tannock IF, Fizazi K, Ivanov S et al (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase III, double-blind randomized trial. Lancet Oncol 14:760–768
Quinn DI, Tangen CM, Hussain M et al (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG 20401): a randomized phase III trial. Lancet Oncol 14:893–900
Araujo JC, Mathev P, Armstrong AJ et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: result from a phase I-II study. Cancer 118:63–71
Fizazi KS, Higano CS, Nelson JB et al (2013) Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patient with metastatic castration-resistant prostate cancer. J Clin Oncol 31:1740–1747
Chi KN, Higano CS, Blumenstein BA et al (2015) Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients with metastatic castration-resistant prostate cancer and poor prognosis. J Clin Oncol 33(suppl; abstr 5009)
Recine F, Ceresoli GL, Baciarello G et al (2015) Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results. Q J Nucl Med Mol Imaging 59:400–410
Buonerba C, Palmieri G, Di Lorenzo G (2010) Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur Urol 58:636–637
Di Lorenzo G, Buonerba C, Faiella A et al (2011) Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 107:234–239
Oudard S, Kramer G, Caffo O et al (2015) Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int 115:744–752
Caffo O, Pappagallo G, Brugnara S et al (2012) Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 79:644–649
Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038
Antonarakis ES, Lu C, Luber B et al (2015) Androgen receptor splice-variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1:582–591
Onstenk W, Sienwerts AM, Kraan J et al (2015) Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 68:935–945
Yap TA, Pezaro CJ, de Bono JS (2012) Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther 12:1129–1136
Seruga B, Ocana A, Tannock IF (2011) Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8:12–23
Tsao CK, Cutting E, Martin J, Oh WK (2014) The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol 6:97–104
Mita AC, Denis LJ, Rowinsky EK et al (2009) Phase I and pharmacokinetic study of XRP6258 (RPR116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15:723–730
Diéras V, Lortholary A, Laurence V et al (2013) Cabazitaxel in patients with advanced solid tumours: results of a phase I and pharmacokinetic study. Eur J Cancer 49:25–34
Pivot X, Koralewski P, Hidalgo J et al (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 9:1547–1552
Villanueva C, Awada A, Campone M et al (2011) A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer 47:1037–1045
Bahl A, Oudard S, Tombal B et al (2012) Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402–2408
Heidenreich A, Scholz HJ, Rogenhofer S et al (2013) Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 63:977–982
Castellano D, Antòn Aparicio LM, Esteban E et al (2014) Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Expert Opin Drug Saf 13:1165–1173
Heidenreich A, Bracarda S, Mason M et al (2014) Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer 50:1090–1099
Bracarda S, Gernone A, Gasparro D et al (2014) Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 10:975–983
Bahl A, Masson S, Malik Z et al (2015) Final quality of life and safety data for patients with mCRPC treated with cabazitaxel in the UK Early Access Programme (EAP). BJU Int 16:880–887
Halabi S, Lin CY, Small EJ et al (2013) Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 105:1729–1737
De Bono J, Hardy-Bessard A, Kim C et al (2016) Phase III non-inferiority study of cabazitaxel 20 mg/m2 versus 25 mg/m2 in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. J Clin Oncol 34(suppl; abstr 5008)
Sartor O, Oudard S, Sengelov L et al (2016) Cabazitaxel versus docetaxel in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a three-arm Phase III study (FIRSTANA). J Clin Oncol 34(suppl; abstr 5006)
Regan MM, O’Donnell EK, Kelly WK et al (2010) Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol 21:312–318
Aparicio AM, Harzstark AL, Corn PG et al (2013) Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19:3621–3630
Lee JL, Ahn JH, Choi MK et al (2014) Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-base chemotherapy failed. Br J Cancer 110:2472–2478
Sternberg CN, Petrylak DP, Sartor O et al (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27:5431–5438
Sternberg CN (2005) Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 96:990–994
Kelland LR, Abel G, McKeage MJ et al (1993) Preclinical antitumor evaluation of bis-acetatoammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53:2581–2586
Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24:1967–2000
Grasso CS, Wu YM, Robinson DR et al (2012) The mutational landscape of lethal castrate resistant prostate cancer. Nature 487:239–243
Macconaill LE, Garraway LA (2010) Clinical implications of the cancer genome. J Clin Oncol 28:5219–5228
Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 331:1553–1558
Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921
Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917
Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134
Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287–294
Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250
Docetaxel and carboplatin in treating patients with metastatic, hormone resistant prostate cancer containing inactivated genes in the BRCA 1/2 pathway (NCT02598895); www.clinicaltrials.gov. Accessed on 29th May 2016.
Moore SR, Reinberg Y, Zhang G (1992) Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 39:411–416
Papandreou CN, Daliani DD, Thall PF et al (2002) Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072–3080
Beltran H, Tomlins S, Aparicio A et al (2014) Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20:2846–2850
Beltran H, Prandi D, Mosquera JM et al (2016) Divergent clonal evolution of castration resistant neuroendocrine prostate cancer. Nat Med 22:298–305
Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176
Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965–3970
Berthold DR, Pond GR, Roessner M et al (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763–2767
James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomized controlled trial. Lancet 387:1163–1177
Gravis G, Boher J-M, Joly F et al (2015) Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: long-term analysis of the GETUG-AFU-15 phase III trial. Eur Urol 70(2):256–262.
Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746
Sprenger C, Uo T, Plymate S (2015) Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants? Ann Oncol 26:1805–1807
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ceresoli, G.L., Bonomi, M., Sauta, M.G. (2017). Chemotherapy. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-42327-2_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42326-5
Online ISBN: 978-3-319-42327-2
eBook Packages: MedicineMedicine (R0)